Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2000

View Archived Issues

Company Profile: Bolder Biotechnology

Progenics begins phase II pediatric trial with PRO-542

All patients dosed in trial of long-acting inhaled formulation of albuterol for asthma

Deltagen obtains license to develop potential AML treatment

FDA grants orphan drug status for Eurogene's Trinam

FeRx and Elan to develop MTC-DOX for treatment of liver cancer

Company Profile: GenStar Therapeutics

R-102444, a prodrug-type 5-HT2 antagonist, as a promising candidate for thrombosis

Maxim receives SBIR grant for development of caspase-inducing drugs

Russian antiretroviral agent effective and well tolerated in the clinic

ArQule and SmithKline Beecham partner for drug discovery

PDL to humanize antibody for InterMune

Mechanism of action of thalidomide in Crohn's disease investigated as part of clinical trial

New target for IBD treatment discussed at UEGW: leukocyte-platelet aggregation

ProdiGene receives NIH grant for development of AIDS vaccine from transgenic plants

Micrologix initiates phase Ib study for drug candidate active against S. aureus

Secondary efficacy measures improved by ISIS-2302 treatment in Crohn's disease

Abgenix and CuraGen expand genomics-based antibody drug alliance

Nonimidazole histamine H3 antagonists with excellent oral activity in mouse brain

Antibiotic properties discovered for new aromatic amides synthesized at Aventis

Nitric oxide synthase inhibitors for inflammation and pain described by AstraZeneca

Vertex presents newest JNK protein kinase inhibitors in recent patent

Preparation and use of new azepinoindole 5-HT receptor ligands from Pharmacia

Ziprasidone pharmaceutical formulations with good solubility properties

U.K. scientists investigate novel series of antitumor agents

Scotia submits additional data to FDA for Foscan NDA

Imifuramine: synthesis of a novel histamine H3 receptor agonist

Novel H3 receptor agonists show full agonist activity in vivo after oral dosing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...